Department of General Surgery, Affiliated First People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200080, China.
Cancer Lett. 2011 Jul 28;306(2):214-22. doi: 10.1016/j.canlet.2011.03.009. Epub 2011 Apr 11.
Molecular biomarker has been proposed to improve patient selection and post-transplant prognostication, but rare achievement has been made. In the present study, Forkhead box M1 (FOXM1) expression and its prognostic role have been investigated in hepatocellular carcinoma (HCC) treated by orthotopic liver transplantation (OLT). We found that the notably higher level of FOXM1 in tumors was associated with malignant pathological features of HCC and unfavorable outcome after OLT. The status of FOXM1 expression combined with the Milan criteria could make the prognostication more accurate and may be of particular interest for expanding the criteria in selecting transplant candidates.
分子生物标志物被提议用于改善患者选择和移植后预后预测,但取得的成果很少。在本研究中,我们研究了 Forkhead box M1(FOXM1)在接受原位肝移植(OLT)治疗的肝细胞癌(HCC)中的表达及其预后作用。我们发现,肿瘤中 FOXM1 水平显著升高与 HCC 的恶性病理特征和 OLT 后不良预后相关。FOXM1 表达状态结合米兰标准可以使预后更准确,对于扩大移植候选者的选择标准可能具有特别的意义。